CASP3 and neoplasm: Is it possible that their immune system is capable of destroying tumor repopulating “outliers” within a tumor (e.g., PGCCs, oncogenic caspase 3-acivated cells) before they will have the opportunity to promote tumor progression (through secretory factors) and to give rise to tumor repopulating progeny, or perhaps such “outliers” are not present at significant frequencies in the tumors of these patients (before and after therapy) in the first place?